宋博凡,高方明

• 1:新疆医科大学研究生学院

摘要(Abstract)：

<正>氯吡格雷联合阿司匹林仍然是国内冠状动脉粥样硬化性心脏病(冠心病)患者抗血小板治疗的首选药物,而氯吡格雷更是目前抗血小板治疗的基石。经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后接受氯吡格雷常规口服剂量治疗的临床疗效显著,但是存在明显的个体差异,仍有部分患者再发心血管缺血事件,如支架内血栓、急性心肌梗死、猝死等。氯吡格雷抵抗为氯吡格雷低反应可能

关键词(KeyWords)： 氯吡格雷;基因多态性;抗血小板治疗;个体化治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 宋博凡,高方明

参考文献(References)：

• [1]Price MJ,Murray SS,Angiolillo DJ,et al.Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention:the GIFT(Genotype Information and Functional Testing)study.Am Coll Cardiol,2012,59:1928-1937.
• [2]Wu H,Qian J,Sun A,et al.Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.Circ J,2012,76:2773-2778.
• [3]Zhang L,Chen Y,Jin Y,et al.Genetic determinants of high ontreatment platelet reactivity in clopidogrel treated Chinese patients.Thromb Res,2013,132:81-87.
• [4]ParéG,Mehta SR,Yusuf S,et al.Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.N Engl J Med,2010,363:1704-1714.
• [5]Park J.Backtracking on CYP2C19 genotyping in clopidogrel therapy?Biomark Med,2010,4:791.
• [6]李韶南,刘震,罗义,等.细胞色素P450 2C19基因多态性与急性冠状动脉综合征患者氯吡格雷抵抗及预后关系.中华内科杂志,2013,52:961-965.
• [7]夏金喜,肖建民,万德立,等.急性冠脉综合征PCI术后患者CYP2C19*2、CYP2C19*3基因多态性与氯吡格雷抵抗及临床预后的关系.中国心血管病研究,2015,13:731-734.
• [8]吴丹,杨胜利,路靖,等.冠心病患者支架术后根据检测药物代谢酶CYP2C19基因调整抗血小板治疗的价值.中国循环杂志,2015,30:216-219.
• [9]Jang JS,Cho KI,Jin HY,et al.Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.Am J Cardiol,2012,110:502-508.
• [10]Chen DY,Wang CY,Wen MS,et al.Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population.PLo S One,2012,7:e39178.
• [11]刘茂,陈剑,钟桃娟,等.细胞色素CYP2C19*2基因多态性对冠心病氯吡格雷服用者预后影响的Meta分析.重庆医学,2014,43:3708-3712.
• [12]Tresukosol D,Suktitipat B,Hunnangkul S,et al.Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.PLo S One,2014,9:e110188.
• [13]Delaney JT,Ramirez AH,Bowton E,et al.Predicting clopidogrel response using DNA samples linked to an electronic health record.Clin Pharmacol Ther,2012,91:170-171.
• [14]康彦红,劳海燕,陈秀云,等.PON1基因启动子多态性及非遗传因素对PCI术后抗血小板治疗临床效应的影响.中国药理学通报,2012,28:1682-1686.
• [15]Luo M,Li J,Xu X,et al.ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients:a meta-analysis.Thromb Res,2012,129:754-759.
• [16]Wang XD,Zhang DF,Liu XB,et al.Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance.Eur J Intern Med,2012,23:48-53.
• [17]Barker CM,Murray SS,Teirstein PS,et al.Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high ontreatment reactivity.JACC Cardiovasc Interv,2010,3:1008-1010.
• [18]Mega JL,Hochholzer W,Frelinger AL 3rd,et al.Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.JAMA,2011,306:2221-2228.
• [19]刘然,师树田,索旻,等.对氯吡格雷低反应患者换用替格瑞洛后的有效性与安全性评价.中国介入心脏病学杂志,2014,22:12-17.
• [20]Latkovskis G,Urtane I,Knipse A,et al.Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hypo responsiveness.Medicina(Kaunas),2014,50:19-27.
• [21]Gladding P,Webster M,Zeng I,et al.The pharmacogenetics and pharmacodynamics of clopidogrel response:an analysis from the PRINC(Plavix Response in Coronary Intervention)trial.JACC Cardiovasc Interv,2008,1:620-627.
• [22]Collet JP,Hulot JS,Anzaha G,et al.High doses of clopidogrel to overcome genetic resistance:the randomized crossover CLOVIS-2(Clopidogrel and Response Variability Investigation Study 2).JACC Cardiovas Interv,2011,4:392-402.
• [23]Cuisset T,Quilici J,Cohen W,et al.Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.Am J Cardiol,2011,108:760-765.
• [24]Jeong YH,Kim IS,Park Y,et al.Carriage of cytochrome 2C19polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150mg/day:results of the ACCEL-DOUBLE(Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism)study.JACC Cardiovasc Interv,2010,3:731-741.
• [25]Jneid H,Anderson JL,Wright RS,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2012,60:645-681.
• [26]Mehta SR,Yusuf S,Peters RJ,et al.Effects of pretreatment with elopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study.Lancet,2001,358:527-533.
• [27]Mehta SR,Tanguay JF,Eikelboom JW,et al.Double-dose versus standard-dose elopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes(CURRENT-OASIS 7):a randomised factorial trial.Lancet,2010,376:1233-1243.
• [28]Terpening C.Clopidogrel:a pharmacogenormic perspective on its use in coronary artery disease.Clin Med Insights Cardiol,2010,4:117-128.
• [29]Siller-Matula JM,Huber K,Christ G,et al.Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention:a systematic review and meta-analysis.Heart,2011,97:98-105.